Facts
- HQ
- New York, NY, US
- Sectors
- Investment Management
- Founded
- 1989
- Employees
- 169
Nautilus Biotechnology (NAUT) goes public via SPAC, raises $345 million to commercialize proteome analysis
Nautilus Biotechnology, co-founded by Sujal Patel and Parag Mallick, is going public on Nasdaq as NAUT through a SPAC merger that raised $345 million to advance a new proteome analysis platform aimed at accelerating biomedical research and drug development. Institutional backers include Bezos Expeditions, Vulcan Capital and Madrona Venture Group, and the deal closes on the 25th anniversary of Patel’s arrival in Seattle.
Nautilus Biotechnology to go public via Arya Sciences Acquisition Corp III SPAC, raising $350M at $900M valuation
Nautilus Biotechnology, a Seattle proteomics startup led by Sujal Patel and Parag Mallick, will go public via a SPAC merger with Arya Sciences Acquisition Corp III, raising about $350 million and valuing the company at $900 million. The deal includes a $150 million SPAC component and a $200 million PIPE, expects to close in Q2, and the combined company will trade on Nasdaq as NAUT.
GentiBio raises $20M seed round, licenses Treg technologies from Seattle Children’s, BRI and MIGAL
Boston-based GentiBio raised $20 million in a seed funding round and signed licensing deals with Seattle Children’s Research Institute, Benaroya Research Institute (BRI), and MIGAL to develop engineered regulatory T cells for autoimmune, alloimmune, autoinflammatory, and allergic diseases.
